Association of Lipid Mediators With Development of Future Incident Inflammatory Arthritis in an Anti-Citrullinated Protein Antibody-Positive Population
Overview
Authors
Affiliations
Objective: To determine the association of polyunsaturated fatty acid (PUFA)-derived lipid mediators with progression from rheumatoid arthritis (RA)-related autoimmunity to inflammatory arthritis (IA).
Methods: We conducted a prospective cohort study using data from the Studies of the Etiology of Rheumatoid Arthritis (SERA). SERA enrolled first-degree relatives (FDRs) of individuals with RA (FDR cohort) and individuals who screened positive for RA-related autoantibodies at health fairs (screened cohort). We followed up 133 anti-cyclic citrullinated peptide 3.1 (anti-CCP3.1)-positive participants, 29 of whom developed IA. Lipid mediators selected a priori were quantified from stored plasma samples using liquid chromatography tandem mass spectrometry. We fit multivariable Cox proportional hazards models for each lipid mediator as a time-varying variable. For lipid mediators found to be significantly associated with IA, we then examined interleukin-1β (IL-1β), IL-6, IL-8, and tumor necrosis factor (TNF) as potential statistical mediators.
Results: For every 1 natural log pg/ml increase in the circulating plasma levels of proinflammatory 5-HETE, the risk of developing IA increased by 241% (hazard ratio 2.41 [95% confidence interval 1.43-4.07]) after adjusting for age at baseline, cohort (FDR or screened), and shared epitope status. The models examining 15-HETE and 17-HDHA had the same trend but did not reach significance. We did not find evidence that the association between 5-HETE and IA risk was influenced by the proinflammatory cytokines tested.
Conclusion: In a prospective cohort of anti-CCP-positive individuals, higher levels of 5-HETE, an important precursor to proinflammatory leukotrienes, is associated with subsequent IA. Our findings highlight the potential significance of these PUFA metabolites in pre-RA populations.
Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis.
Holers V, Demoruelle K, Buckner J, James E, Firestein G, Robinson W Nat Rev Rheumatol. 2024; 20(10):601-613.
PMID: 39251771 DOI: 10.1038/s41584-024-01154-0.
ONeil L, Anaparti V, Winter T, Smolik I, Meng X, Aukema H Arthritis Res Ther. 2024; 26(1):51.
PMID: 38360827 PMC: 10868017. DOI: 10.1186/s13075-024-03274-0.
Eicosanoid profiles in an arthritis model: Effects of a soluble epoxide hydrolase inhibitor.
Trindade-da-Silva C, Yang J, Fonseca F, Pham H, Napimoga M, Abdalla H Biochim Biophys Acta Mol Cell Biol Lipids. 2023; 1869(2):159432.
PMID: 37984607 PMC: 10842726. DOI: 10.1016/j.bbalip.2023.159432.
Charles-Schoeman C, Wang J, Shahbazian A, Wilhalme H, Brook J, Kaeley G Rheumatol Int. 2023; 43(6):1041-1053.
PMID: 36828925 PMC: 10125943. DOI: 10.1007/s00296-023-05285-7.
Mechanism-driven strategies for prevention of rheumatoid arthritis.
Holers V, Kuhn K, Demoruelle M, Norris J, Firestein G, James E Rheumatol Autoimmun. 2022; 2(3):109-119.
PMID: 36312783 PMC: 9610829. DOI: 10.1002/rai2.12043.